Skip to nav Skip to content
Scott  Gilbert

Scott Gilbert, MD

4.9 (378)

Specialty: Urology

Program: Genitourinary Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Bladder Cancer, Kidney (Renal Cell) Cancer, Testicular Cancer

    Dr. Gilbert received his MD degree from Columbia University, College of Physicians & Surgeons, and he completed a Residency in the Department of Urology at New York-Presbyterian Hospital - Columbia University Medical Center, where he served as Chief Resident, in 2005. He completed the following Fellowships at the University of Michigan Health Systems: Health Services Research Fellow (7/2005-6/2008) and Urologic Oncology Fellow (7/2006-6/2008).Dr. Gilbert joined Moffitt in 2014 after serving as Assistant Professor at the University of Florida College of Medicine from 2008 – 2014. Dr. Gilbert’s clinical practice focuses on the surgical and multidisciplinary management of urologic cancers, including, bladder, kidney, and testis cancers. He has particular interest and expertise in bladder and testis cancer, and offers open, laparoscopic and robot-assisted procedures, nerve and organ-sparing approaches, and complex salvage and reconstructive surgeries. His research interests are in Cancer Care Delivery and Patient Reported Outcomes Research among patients with urologic malignancies.

    Education & Training


    • University of Michigan Health Systems - Urology, Urology Oncology, Health Services Research Fellow


    • New York-Presbyterian Hospital Columbia University Medical Center - Urology

    Medical School:

    • Columbia University, College of Physicians & Surgeons - MD
  • Publications

    • Huelster HL, Mason NT, Davaro F, Naqvi SMH, Kim Y, Gilbert SM. Cost-utility of Initial Management of High-grade T1 Bladder Cancer With Intravesical BCG vs Immediate Radical Cystectomy. Urology. 2024 May.187:106-113. Pubmedid: 38467285.
    • Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Jun. Pubmedid: 38837106.
    • Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jun.7(3):614-624. Pubmedid: 38184473.
    • Paravathaneni M, Safa H, Joshi V, Tamil MK, Adashek JJ, Ionescu F, Shah S, Chadha JS, Gilbert S, Manley B, Semaan A, Jim HSL, Kalos D, Kim Y, Spiess PE, Chahoud J. 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. EClinicalMedicine. 2024 Feb.68:102413. Pubmedid: 38273886. Pmcid: PMC10809115.
    • Grassauer J, Schmidt J, Cowan A, Gilbert SM, Chakiryan NH. Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer. Eur Urol Oncol. 2024 Feb.7(1):139-146. Pubmedid: 37453853.
    • Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 Apr.42(4):116.e17-116.e21. Pubmedid: 38087711.
    • Rollison DE, Gonzalez BD, Turner K, Jim HSL, Zhao Y, Amorrortu RP, Howard R, Ghia KM, Ngo B, Reisman P, Moore C, Perkins R, Keenan RJ, Sallman DA, Naso CM, Robinson EJ, Vadaparampil ST, Simmons VN, Schabath MB, Gilbert SM. Examining disparities in large-scale patient-reported data capture using digital tools among cancer patients at clinical intake. Cancer Med. 2023 Sep.12(18):19033-19046. Pubmedid: 37596773. Pmcid: PMC10557830.
    • Davaro F, Davaro E, Rose K, Murthy P, Naidu S, Camperlengo L, Grass GD, Vosoughi A, Jain RK, Zemp L, Yu A, Poch MA, Spiess PE, Gilbert SM, Sexton WJ, Li R. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):389.e7-389.e13. Pubmedid: 36959058.
    • Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
    • Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
    • Amorrortu RP, Zhao Y, Keenan RJ, Gilbert SM, Rollison DE. Factors Associated with Self-reported COVID-19 Infection and Hospitalization among Patients Seeking Care at a Comprehensive Cancer Center. J Racial Ethn Health Disparities. 2023 Nov. Pubmedid: 37917235.
    • Gilbert SM. Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not. J Urol. 2023 May.209(5):833-835. Pubmedid: 36893473.
    • Murthy PB, Naidu S, Davaro F, Spiess PE, Zemp L, Poch M, Jain R, Vosoughi A, Grass GD, Yu A, Sexton WJ, Gilbert SM, Li R. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Curr Oncol. 2023 Mar.30(3):3223-3231. Pubmedid: 36975458. Pmcid: PMC10046994.
    • Mason NT, Joshi VB, Adashek JJ, Kim Y, Shah SS, Schneider AM, Chadha J, Jim HSL, Byrne MM, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023 Jun.6(3):331-338. Pubmedid: 36797084.
    • Turner K, Stover AM, Tometich DB, Geiss C, Mason A, Nguyen OT, Hume E, McCormick R, Powell S, Hallanger-Johnson J, Patel KB, Kirtane KS, Jammigumpula N, Moore C, Perkins R, Rollison DE, Jim HSL, Oswald LB, Crowder S, Gonzalez BD, Robinson E, Tabriz AA, Islam JY, Gilbert SM. Oncology Providers' and Professionals' Experiences With Suicide Risk Screening Among Patients With Head and Neck Cancer: A Qualitative Study. JCO Oncol Pract. 2023 Jun.19(6):e892-e903. Pubmedid: 36395441. Pmcid: PMC10337750.
    • Hugar LA, Geiss C, Chavez MN, Gore LR, Thirlwell S, Reblin M, Gilbert SM. Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed methods analysis. Urol Oncol. 2023 Jul.41(7):327.e19-327.e26. Pubmedid: 37225636.
    • Huelster HL, Zemp L, Turner K, Gonzalez BD, Jim H, Gore LR, Gilbert SM. Mobile Postoperative Symptom Intervention Tool and Biometric Monitoring After Radical Cystectomy: Pilot Study Evaluating Feasibility, Usability, and Potential Utility. J Urol. 2023 Feb.209(2):410-421. Pubmedid: 36350586. Pmcid: PMC10316518.
    • Filippou P, Hugar LA, Louwers R, Pomper A, Chisolm S, Smith AB, Gore JL, Gilbert SM. Palliative care knowledge, attitudes, and experiences amongst patients with bladder cancer and their caregivers. Urol Oncol. 2023 Feb.41(2):108.e1-108.e9. Pubmedid: 36529652.
    • Powers BD, McDonald J, Mhaskar R, Lee SJC, Permuth JB, Vadaparampil S, Gilbert SM, Denbo JW, Kim DW, Pimiento JM, Hodul PJ, Malafa MP, Anaya DA, Fleming JB. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Ann Surg Open. 2022 Sep.3(3):e197. Pubmedid: 36199487. Pmcid: PMC9508964.
    • Hugar LA, Gilbert SM, Li R. Editorial Comment. J Urol. 2022 Sep.208(3):578. Pubmedid: 35942791.
    • Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
    • Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2022 May.5(5):e2212347. Pubmedid: 35576003. Pmcid: PMC9112069.
    • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
    • Rose KM, Huelster HL, Roberts EC, Manley BJ, Gilbert SM, Sexton WJ. Contemporary Management of Chylous Ascites after Retroperitoneal Surgery: Development of an Evidence-Based Treatment Algorithm. J Urol. 2022 Jul.208(1):53-61. Pubmedid: 35212572.
    • Stetson PD, McCleary NJ, Osterman T, Ramchandran K, Tevaarwerk A, Wong T, Sugalski JM, Akerley W, Mercurio A, Zachariah FJ, Yamzon J, Stillman RC, Gabriel PE, Heinrichs T, Kerrigan K, Patel SB, Gilbert SM, Weiss E. Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group. J Natl Compr Canc Ne. 2022 Jan.1-6. Pubmedid: 35042190.
    • Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
    • Li R, Gilbert SM. Editorial Comment. J Urol. 2022 Feb.207(2):312-313. Pubmedid: 34994655.
    • Chadha J, Adashek JJ, Jim H, Kim Y, Semaan A, Chakiryan NH, Safa H, Hajiran A, Sexton W, Gilbert SM, Manley BJ, Spiess PE, Chahoud J. Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients' Voice or a Miss. Clin Genitourin Cancer. 2022 Apr.20(2):e158-e165. Pubmedid: 34974985.
    • Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 Apr.40(4):164.e1-164.e7. Pubmedid: 34629281. Pmcid: PMC8960322.
    • Li R, Zhang J, Gilbert SM, Conejo-Garcia J, Mulé JJ. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021 Sep.18(9):543-555. Pubmedid: 34183833.
    • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
    • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
    • Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert S, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May.113(5):532-542. Pubmedid: 33146385. Pmcid: PMC8096374.
    • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
    • Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
    • Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 Mar.31(2):160-169. Pubmedid: 33394766.
    • Hajiran A, Azizi M, Aydin AM, Chakiryan NH, Peyton CC, Boulware DC, Manley BJ, Gilbert SM, Sexton WJ. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol. 2021 Jul.28(7):3648-3655. Pubmedid: 33689081. Pmcid: PMC9801512.
    • Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. 2021 Jul.80(1):1-3. Pubmedid: 32861573. Pmcid: PMC7448869.
    • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
    • Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
    • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
    • Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
    • Jim HSL, Hoogland AI, Brownstein NC, Barata A, Dicker AP, Knoop H, Gonzalez BD, Perkins R, Rollison D, Gilbert SM, Nanda R, Berglund A, Mitchell R, Johnstone PAS. Innovations in research and clinical care using patient-generated health data. CA-Cancer J Clin. 2020 May.70(3):182-199. Pubmedid: 32311776. Pmcid: PMC7488179.
    • Lee CT, Mohamed NE, Pisipati S, Shah QN, Agarwal PK, Downs TM, Droller M, Gilbert SM, Goltz HH, Hall SJ, Hendawi M, Hoffman-Censits J, O'Donnell M, Kaag M, Karsh LI, Kassouf W, Quale DZ, Sagalowsky A, Steinberg GD, Latini DM. Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach. BMC Health Serv Res. 2020 Jul.20(1):686. Pubmedid: 32709234. Pmcid: PMC7379822.
    • Sexton WJ, Gilbert SM. Focused issue on testicular cancer-forward. Transl Androl Urol. 2020 Jan.9(Suppl 1):S1-S2. Pubmedid: 32055479. Pmcid: PMC6995848.
    • Cheriyan SK, Nicholson M, Aydin AM, Azizi M, Peyton CC, Sexton WJ, Gilbert SM. Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors. Transl Androl Urol. 2020 Jan.9(Suppl 1):S45-S55. Pubmedid: 32055485. Pmcid: PMC6995850.
    • Azizi M, Peyton CC, Boulware DC, Gilbert SM, Sexton WJ. Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival. Urol Oncol. 2020 Jan.38(1):7.e9-7.e18. Pubmedid: 31704139. Pmcid: PMC7771339.
    • Check DK, Leo MC, Banegas MP, Bulkley JE, Danforth KN, Gilbert SM, Kwan ML, O'Keeffe Rosetti M, McMullen CK. Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy. J Urol. 2020 Jan.203(1):159-163. Pubmedid: 31441673.
    • Azizi M, Aydin AM, Cheriyan SK, Peyton CC, Montanarella M, Gilbert SM, Sexton WJ. Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors. Transl Androl Urol. 2020 Jan.9(Suppl 1):S91-S103. Pubmedid: 32055490. Pmcid: PMC6995843.
    • Peyton CC, Hajiran A, Morgan K, Azizi M, Tang D, Chipollini J, Gilbert SM, Poch M, Sexton WJ, Spiess PE. Urinary leak following partial nephrectomy: a contemporary review of 975 cases. Can J Urol. 2020 Feb.27(1):10118-10124. Pubmedid: 32065869.
    • Sessine M, Weizer A, Kirk PS, Borza T, Jacobs BL, Qin Y, Oerline M, Li B, Modi PK, Lavieri MS, Gilbert SM, Montgomery JS, Hollenbeck BK, Urish K, Helm JE, Skolarus TA. Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. Urology. 2020 Aug.142:99-105. Pubmedid: 32413517.
    • Kirk PS, Liu X, Borza T, Li BY, Sessine M, Zhu K, Lesse O, Qin Y, Jacobs B, Urish K, Helm J, Gilbert S, Weizer A, Montgomery J, Hollenbeck BK, Lavieri M, Skolarus TA. Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. Urol Oncol. 2020 Apr.38(4):255-261. Pubmedid: 31953004.
    • Gilbert SM, Sexton WJ. Optimal Management of High-risk Stage I Nonseminoma Germ Cell Tumor: Active Intervention is the Preferred Option. Eur Urol Focus. 2019 Sep.5(5):704-705. Pubmedid: 31564641.
    • Peyton CC, Reich RR, Tang D, Alford B, Azizi M, Li R, Sexton WJ, Poch M, Gilbert SM. Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review. J Urol. 2019 Nov.202(5):913-919. Pubmedid: 31219762. Pmcid: PMC7864380.
    • Gilbert SM. EDITORIAL COMMENT. Urology. 2019 May.125:152-153. Pubmedid: 30798964.
    • Kwan ML, Leo MC, Danforth KN, Weinmann S, Lee VS, Munneke JR, Bulkley JE, Rosetti MO, Yi DK, Banegas MP, Wagner MD, Williams SG, Aaronson DS, Grant M, Krouse RS, Gilbert SM, McMullen CK. Factors That Influence Selectionof Urinary Diversion Among Bladder Cancer Patients in 3 Community-based Integrated Health Care Systems. Urology. 2019 Mar.125:222-229. Pubmedid: 30471370. Pmcid: PMC6389399.
    • Leo MC, Gilbert SM, Wendel CS, Krouse RS, Grant M, Danforth KN, Kwan ML, Harrison TN, Bulkley JE, McMullen CK. Development of a Goal Elicitation Measure to Support Choice about Urinary Diversion by Patients with Bladder Cancer. J Urol. 2019 Jul.202(1):83-89. Pubmedid: 30835627.
    • Li R, Spiess PE, Gilbert SM, Necchi A. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. 2019 Jul.76(1):4-6. Pubmedid: 30833139.
    • Faba OR, Tyson MD, Artibani W, Bochner BH, Burkhard F, Gilbert SM, Kälble T, Madersbacher S, Seiler R, Skinner EC, Thalmann G, Thüroff J, Wiklund P, Hautmann R, Palou J. Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. World J Urol. 2019 Jan.37(1):85-93. Pubmedid: 30238399.
    • McMullen CK, Kwan ML, Colwell JC, Munneke JR, Davis JV, Firemark A, Brooks N, Grant M, Gilbert SM, Altschuler A. Recovering from Cystectomy: Patient Perspectives. Bladder Cancer. 2019 Jan.5(1):51-61. Pubmedid: 30854413. Pmcid: PMC6401661.
    • Lee AJ, Liu X, Borza T, Qin Y, Li BY, Urish KL, Kirk PS, Gilbert S, Hollenbeck BK, Helm JE, Lavieri MS, Skolarus TA, Jacobs BL. Role of Post-Acute Care on Hospital Readmission After High-Risk Surgery. J Surg Res. 2019 Feb.234:116-122. Pubmedid: 30527462. Pmcid: PMC6291841.
    • Kirk PS, Skolarus TA, Jacobs BL, Qin Y, Li B, Sessine M, Liu X, Zhu K, Gilbert SM, Hollenbeck BK, Urish K, Helm J, Lavieri MS, Borza T. Characterising 'bounce-back' readmissions after radical cystectomy. BJU Int. 2019 Dec.124(6):955-961. Pubmedid: 31313473. Pmcid: PMC6879782.
    • Li R, Spiess PE, Gilbert SM, Necchi A. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Eur Urol. 2019 Aug.76(2):e34. Pubmedid: 31056228.
    • Peyton CC, Henriksen C, Reich RR, Azizi M, Gilbert SM. Estimating Minimally Important Differences for the Bladder Cancer Index Using Distribution and Anchor Based Approaches. J Urol. 2019 Apr.201(4):709-714. Pubmedid: 30342063. Pmcid: PMC7811779.
    • Patel SY, Garcia Getting RE, Alford B, Hussein K, Schaible BJ, Boulware D, Lee JK, Gilbert SM, Powsang JM, Sexton WJ, Spiess PE, Poch MA. Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center. World J Surg. 2018 Sep.42(9):2701-2707. Pubmedid: 29750321. Pmcid: PMC7771278.
    • Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer. 2018 Oct.16(5):e1003-e1013. Pubmedid: 29859736.
    • Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY. Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center. BMC Anesthesiol. 2018 Nov.18(1):157. Pubmedid: 30390636. Pmcid: PMC6215353.
    • Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol. 2018 Nov.4(11):1535-1542. Pubmedid: 30178038. Pmcid: PMC6248089.
    • Gilbert SM. Editorial Comment. J Urol. 2018 Mar.199(3):674-675. Pubmedid: 29175234.
    • Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018 Jul.7(9):e1476816. Pubmedid: 30228944. Pmcid: PMC6140546.
    • Chipollini J, Tang DH, Manimala N, Gilbert SM, Pow-Sang JM, Sexton WJ, Poch MA, Spiess PE. Evaluating the accuracy of intraoperative frozen section during inguinal lymph node dissection in penile cancer. Urol Oncol. 2018 Jan.36(1):14.e1-14.e5. Pubmedid: 29032883.
    • Gilbert SM. Quality of Life and Urinary Diversion. Urol Clin North Am. 2018 Feb.45(1):101-111. Pubmedid: 29169442.
    • McMullen C, Nielsen M, Firemark A, Price PM, Nakatani D, Tuthill J, McMyn R, Odisho A, Meyers M, Shibata D, Gilbert S. Designing for impact: identifying stakeholder-driven interventions to support recovery after major cancer surgery. Support Care Cancer. 2018 Dec.26(12):4067-4076. Pubmedid: 29876832. Pmcid: PMC6682403.
    • Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol. 2018 Dec.37(10):2017-2029. Pubmedid: 30535583.
    • Clements MB, Schmidt KM, Canfield SE, Gilbert SM, Khandelwal SR, Koontz BF, Lallas CD, Liauw S, Nguyen PL, Showalter TN, Trabulsi EJ, Cathro HP, Schenkman NS, Krupski TL. Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Dec.75(2):434-441. Pubmedid: 28923535.
    • Gilbert SM. WITHDRAWN: Knowledge Gained: Patient-Reported Outcomes Associated with NMIBC. Urology. 2018 Dec. Pubmedid: 30578791.
    • Gilbert SM, Dunn RL, Miller DC, Montgomery JS, Skolarus TA, Weizer AZ, Wood DP, Hollenbeck BK. Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. J Urol. 2017 Sep.198(3):600-607. Pubmedid: 28392393.
    • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May.103:142-148. Pubmedid: 28011275.
    • Borza T, Jacobs BL, Montgomery JS, Weizer AZ, Morgan TM, Hafez KS, Lee CT, Y B, Min HS, He C, Gilbert SM, Helm JE, Lavieri MS, Hollenbeck BK, A Skolarus T. No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. Urology. 2017 Jun.104:77-83. Pubmedid: 28267606. Pmcid: PMC5449208.
    • Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul.105:108-112. Pubmedid: 28342928.
    • Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 Dec.15(6):696-703. Pubmedid: 28566202.
    • Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer. J Urol. 2017 Dec.198(6):1346-1352. Pubmedid: 28652123.
    • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug.15(4):e583-e589. Pubmedid: 28410909. Pmcid: PMC7771283.
    • Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr.35(4):657-663. Pubmedid: 27495912.
    • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 05.103:148. Pubmedid: 28108090.
    • Gilbert SM, Pow-Sang JM, Xiao H. Geographical Factors Associated With Health Disparities in Prostate Cancer. Cancer Control. 2016 Oct.23(4):401-408. Pubmedid: 27842329.
    • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov.34(11):1567-1573. Pubmedid: 27072536.
    • Sharma P, Dunn RL, Wei JT, Montie JE, Gilbert SM. Evaluation of point-of-care PRO assessment in clinic settings: integration, parallel-forms reliability, and patient acceptability of electronic QOL measures during clinic visits. Qual Life Res. 2016 Mar.25(3):575-583. Pubmedid: 26373852.
    • Leone AR, Diorio GJ, Spiess PE, Gilbert SM. Contemporary Issues Surrounding Small Renal Masses: Evaluation, Diagnostic Biopsy, Nephron Sparing, and Novel Treatment Modalities. Oncology (Williston Park). 2016 Jun.30(6):507-514. Pubmedid: 27323710.
    • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul.93:130-134. Pubmedid: 27041469.
    • Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan.195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
    • Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA. Treatment of Small Cell Carcinoma of the Bladder With Chemotherapy and Radiation after Transurethral Resection of a Bladder Tumor. Am J Clin Oncol. 2016 Feb.39(1):69-75. Pubmedid: 24517956.
    • Li AY, Filson CP, Hollingsworth JM, He C, Weizer AZ, Hollenbeck BK, Gilbert SM, Hafez KS, Lee CT, Dunn RL, Montgomery JS. Patient-Reported Convalescence and Quality of Life Recovery: A Comparison of Open and Robotic-Assisted Radical Cystectomy. Surg Innov. 2016 Dec.23(6):598-605. Pubmedid: 27354552.
    • Luckenbaugh AN, Hollenbeck BK, Montgomery JS, Lee CT, Gilbert SM, Dunn RL, Friedman JF, Englesbe MJ, Wang SC, Hollingsworth JM. Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy. Bladder Cancer. 2016 Apr.2(2):235-240. Pubmedid: 27376142. Pmcid: PMC4927834.
    • Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov.194(5):1220-1225. Pubmedid: 26055823.
    • Gilbert SM, Dunn RL, Wittmann D, Montgomery JS, Hollingsworth JM, Miller DC, Hollenbeck BK, Wei JT, Montie JE. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic. Cancer. 2015 May.121(9):1484-1491. Pubmedid: 25538017.
    • Emanuels CS, Timmerman KD, Aijaz T, Nguyen TC, Jest N, Drane WE, Gilbert SM, Crispen PL, Su LM, Deitte LA, Dang LH. Displacement of the Spleen Mimicking Renal Cell Cancer Recurrence Post-Nephrectomy: A Case Report. J Kidney Cancer VHL. 2015 Jun.2(3):130-133. Pubmedid: 28326267. Pmcid: PMC5345533.
    • Gilbert SM. Revisiting structure, process, and outcome. Cancer. 2015 Feb.121(3):328-330. Pubmedid: 25339064.
    • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug.22(4):7882-7889. Pubmedid: 26267026.
    • Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, Saigal CS, Pisters L, Michalski J, Sandler HM, Litwin MS, Wei JT. Satisfaction with information used to choose prostate cancer treatment. J Urol. 2014 May.191(5):1265-1271. Pubmedid: 24333514. Pmcid: PMC4283586.
    • Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y, Brathwaite J, Morgan TM, Hafez KS, Weizer AZ, Gilbert SM, Lee CT, Lavieri MS, Helm JE, Hollenbeck BK, Skolarus TA. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May.120(9):1409-1416. Pubmedid: 24477968.
    • Modh RA, Mulhall JP, Gilbert SM. Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol. 2014 Aug.11(8):445-453. Pubmedid: 24980191. Pmcid: PMC4509620.
    • Gilbert SM, Lai J, Saigal CS, Gore JL. Downstream complications following urinary diversion. J Urol. 2013 Sep.190(3):916-922. Pubmedid: 23499749.
    • Gore JL, Gilbert SM. Improving bladder cancer patient care: a pharmacoeconomic perspective. Expert Rev Anticanc. 2013 Jun.13(6):661-668. Pubmedid: 23773101.
    • Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, Gilbert SM, Strope SA, Dunn RL, Miller DC, Hollenbeck BK. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. Jama. 2013 Jun.309(24):2587-2595. Pubmedid: 23800935. Pmcid: PMC3857348.
    • Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK. The impact of technology diffusion on treatment for prostate cancer. Med Care. 2013 Dec.51(12):1076-1084. Pubmedid: 24226306. Pmcid: PMC3916901.
    • Hazariwala R, Morris CG, Gilbert S, Algood C, Zlotecki RA. Radiotherapy for spermatic cord sarcoma. Am J Clin Oncol. 2013 Aug.36(4):392-394. Pubmedid: 22772428.
    • Dahm P, Gilbert S. ACP Journal Club. Radical prostatectomy and observation did not differ for mortality in localized prostate cancer. Ann Intern Med. 2012 Oct.157(8):JC4-JC5. Pubmedid: 23070507.
    • Gilbert SM, Kuo YF, Shahinian VB. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol Oncol. 2012 Mar.29(6):647-653. Pubmedid: 19926311. Pmcid: PMC2888908.
    • Gilbert S. Editorial comment. Urology. 2012 Jun.79(6):1279. Pubmedid: 22521194.
    • Lee CT, Mei M, Ashley J, Breslow G, O'Donnell M, Gilbert S, Lemmy S, Saxton C, Sagalowsky A, Sansgiry S, Latini DM. Patient resources available to bladder cancer patients: a pilot study of healthcare providers. Urology. 2012 Jan.79(1):172-177. Pubmedid: 21996109.
    • Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH. Combination therapy for renal cell cancer: what are possible options?. Oncology-Basel. 2012 Apr.81(3-4):220-229. Pubmedid: 22085914. Pmcid: PMC3225259.
    • Gore JL, Lai J, Gilbert SM. Readmissions in the postoperative period following urinary diversion. World J Urol. 2011 Feb.29(1):79-84. Pubmedid: 21104414. Pmcid: PMC3024518.
    • Gilbert SM, Penson D. Outcomes research in urology. World J Urol. 2011 Feb.29(1):1-2. Pubmedid: 21120504.
    • Hedgepeth RC, Gilbert SM, He C, Lee CT, Wood DP. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology. 2010 Sep.76(3):671-675. Pubmedid: 20451964.
    • Evans B, Montie JE, Gilbert SM. Incontinent or continent urinary diversion: how to make the right choice. Curr Opin Urol. 2010 Sep.20(5):421-425. Pubmedid: 20616739.
    • Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010 Nov.363(19):1822-1832. Pubmedid: 21047226.
    • Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol. 2010 May.183(5):1764-1769. Pubmedid: 20299056.
    • Bradford TJ, Weizer AZ, Gilbert SM, Dunn RL, Wojno K, Shah R, Wood DP. Is residual neurovascular tissue on prostatectomy specimens associated with surgeon intent at nerve-sparing and postoperative quality of life measures?. Urol Oncol. 2010 Dec.28(5):487-491. Pubmedid: 19110450.
    • Dahm P, Gilbert SM, Zlotecki RA, Guyatt GH. How to use an article about prognosis. J Urology. 2010 Apr.183(4):1303-1308. Pubmedid: 20171663.
    • Gilbert SM. Prostate cancer: seminal vesicle sparing: a continuing trend?. Nat Rev Urol. 2009 Sep.6(9):475-476. Pubmedid: 19727146.
    • Strope SA, Wolf JS, Hafez KS, Dunn RL, Hollingsworth JM, Gilbert SM, Hollenbeck BK. Understanding the relationship between health care quality and the renal mass. Urol Oncol. 2009 Jul.27(4):443-447. Pubmedid: 19573776.
    • Gilbert SM, Hollenbeck BK. Limitations of lymph node counts as a measure of therapy. J Natl Compr Canc Ne. 2009 Jan.7(1):58-61. Pubmedid: 19176206.
    • Siu W, Daignault S, Miller DC, Dunn RL, Gilbert S, Weizer AZ, Ye Z, Hollenbeck BK. Understanding differences between high and low volume hospitals for radical prostatectomy. Urol Oncol. 2008 Sep.26(3):260-265. Pubmedid: 18452816.
    • Weizer AZ, Gilbert SM, Roberts WW, Hollenbeck BK, Wolf JS. Tailoring technique of laparoscopic partial nephrectomy to tumor characteristics. J Urology. 2008 Oct.180(4):1273-1278. Pubmedid: 18707711.
    • Gilbert SM. Shifting focus to cancer survivorship in prostate cancer: challenges and opportunities. Curr Opin Urol. 2008 May.18(3):326-332. Pubmedid: 18382244.
    • Gilbert SM, Dunn RL, Miller DC, Daignault S, Ye Z, Hollenbeck BK. Mortality after urologic cancer surgery: impact of non-index case volume. Urology. 2008 May.71(5):906-910. Pubmedid: 18372016.
    • Gilbert SM. Separating surgical quality from causality--gaining perspective in the debate on lymph node count and extent of lymphadenectomy. Cancer. 2008 Jun.112(11):2331-2333. Pubmedid: 18383514.
    • Hollenbeck BK, Dunn RL, Gilbert SM, Strope S, Miller DC. Effects of laparoscopy on surgical discharge practice patterns. Urology. 2008 Jun.71(6):1029-1034. Pubmedid: 18336886.
    • Gilbert SM, Miller DC, Hollenbeck BK, Montie JE, Wei JT. Cancer survivorship: challenges and changing paradigms. J Urol. 2008 Feb.179(2):431-438. Pubmedid: 18076919. Pmcid: PMC2665172.
    • Gilbert SM, Daignault S, Weizer AZ, Wei JT, Hollenbeck BK. The use of tumor markers in testis cancer in the United States: a potential quality issue. Urol Oncol. 2008 Aug.26(2):153-157. Pubmedid: 18312934.
    • Hollenbeck BK, Dunn RL, Wolf JS, Sanda MG, Wood DP, Gilbert SM, Weizer AZ, Montie JE, Wei JT. Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery. Qual Life Res. 2008 Aug.17(6):915-926. Pubmedid: 18574712. Pmcid: PMC2700337.
    • Gilbert SM, Montie JE. Determining when to recommend continent urinary diversion. Can Urol Assoc J. 2008 Aug.2(4):407-409. Pubmedid: 18781217. Pmcid: PMC2532553.
    • Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol. 2007 Nov.25(6):460-464. Pubmedid: 18047952.
    • Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer. 2007 May.109(9):1756-1762. Pubmedid: 17366596.
    • Hensle TW, Gilbert SM. A review of metabolic consequences and long-term complications of enterocystoplasty in children. Curr Urol Rep. 2007 Mar.8(2):157-162. Pubmedid: 17303022.
    • Hollenbeck BK, Daignault S, Dunn RL, Gilbert S, Weizer AZ, Miller DC. Getting under the hood of the volume-outcome relationship for radical cystectomy. J Urol. 2007 Jun.177(6):2095-2099. Pubmedid: 17509295.
    • Gilbert SM. Reliable measurement in urology: room for improvement. Eur Urol. 2007 Jul.52(1):1-2. Pubmedid: 17467163.
    • Gilbert SM, Dunn RL, Wei JT. Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978. J Urol. 2007 Apr.177(4):1584-1585. Pubmedid: 17382782.
    • Gilbert SM, Whitson JM, Mansukhani M, Buttyan R, Benson MC, Olsson CA, Sawczuk IS, McKiernan JM. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology. 2006 May.67(5):942-945. Pubmedid: 16698354.
    • Gilbert SM, McKiernan JM. The role of bisphosphonates in preventing skeletal complications of hormonal therapy. Urol Clin North Am. 2006 May.33(2):191-9, vi. Pubmedid: 16631457.
    • Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology. 2006 Feb.67(2):260-264. Pubmedid: 16461075.
    • Gilbert SM, Lee CT. A case of T2 muscle-invasive bladder cancer treated with neoadjuvant chemotherapy. Nat Clin Pract Urol. 2006 Dec.3(12):675-679. Pubmedid: 17149384.
    • Gilbert SM, Murphy AM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology. 2006 Aug.68(2):287-291. Pubmedid: 16904438.
    • Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005 Mar.65(3):549-553. Pubmedid: 15780374.
    • Murphy AM, Gilbert SM, Katz AE, Goluboff ET, Sawczuk IS, Olsson CA, Benson MC, McKiernan JM. Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU Int. 2005 Jan.95(1):27-30. Pubmedid: 15638890.
    • Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol. 2005 Jan.15(1):23-27. Pubmedid: 15586025.
    • Gilbert SM, Hensle TW. Metabolic consequences and long-term complications of enterocystoplasty in children: a review. J Urol. 2005 Apr.173(4):1080-1086. Pubmedid: 15758705.
    • Gilbert SM, DeCastro GJ, Benson MC. Large multilocular Müllerian duct cyst presenting as pelvic mass. Urology. 2004 Aug.64(2):375. Pubmedid: 15302500.
    • Gilbert SM, Russo P, Benson MC, Olsson CA, McKiernan JM. The evolving role of partial nephrectomy in the management of renal cell carcinoma. Curr Oncol Rep. 2003 May.5(3):239-244. Pubmedid: 12667422.
    • Gilbert SM, Olsson CA, Benson MC, McKiernan JM. The role of intravenous zoledronic acid in the management of high-risk prostate cancer. Curr Opin Urol. 2003 Mar.13(2):133-135. Pubmedid: 12584473.
    • Gilbert SM, Veltri RW, Sawczuk A, Shabsigh A, Knowles DR, Bright S, O'Dowd GJ, Olsson CA, Benson MC, Sawczuk IS. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology. 2003 Mar.61(3):539-543. Pubmedid: 12639642.
    • Lowe FC, Gilbert SM, Kahane H. Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002. Urology. 2003 Dec.62(6):1045-1049. Pubmedid: 14665352.
    • Gilbert SM, Benson MC, McKiernan JM. Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population. Curr Urol Rep. 2002 Jun.3(3):189-193. Pubmedid: 12084187.
    • Vogel B, Gilbert SM, Boylston Herndon J, Dahm P. Advanced topics in evidence-based urologic oncology: economic analysis. Urol Oncol. 29(4):454-461. Pubmedid: 21726796.
  • Grants

    Title: Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Recurrent Bladder Cancer
    Sponsor: Patient Ctr Outcomes Research Institute (PCORI)
    PI: Gilbert, S.
  • Patient Comments

    Overall Satisfaction


    378 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor